Health Logic Interactive Receives Letter of Support from the Chief of the Division of Nephrology at Johns Hopkins University School of Medicine
Health Logic Interactive Inc. (TSXV: CHIP.H, OTC: CHYPF) announced the receipt of a supportive letter from Dr. Chirag R. Parikh, Director of Nephrology at Johns Hopkins University, endorsing its lab-on-chip device for early detection of chronic kidney disease (CKD). Dr. Parikh highlighted the device's potential to enhance screening for CKD, addressing a critical need for accessible monitoring solutions. Additionally, Health Logic was featured in Stat News, further solidifying its position in the health tech space. The company's mission focuses on empowering patients with early detection and actionable management for CKD.
- Received a letter of support from a prominent nephrologist which could enhance credibility.
- Potential market need for accessible CKD screening solutions identified by renowned medical expert.
- Featured in a respected publication, improving visibility in the health technology sector.
- None.
TSXV: CHIP.H
CALGARY, AB, May 26, 2021 /PRNewswire/ - Health Logic Interactive Inc. ("Health Logic" or the "Company") (TSXV: CHIP.H)(OTCPK: CHYPF), is pleased to announce its wholly-owned operating subsidiary, My Health Logic Inc. ("My Health Logic"), has received a letter of support on the Company's chronic kidney disease (CKD) technology from nephrologist Chirag R. Parikh, MD, PhD Director, Division of Nephrology at Johns Hopkins University School of Medicine. This letter supports the Company's belief that its lab-on-chip device for the early detection of CKD has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD.
In his support letter, Dr. Parikh stated, "As the Chief of the Division of Nephrology and the Ronald Peterson Professor of Medicine at the Johns Hopkins University School of Medicine, I have the responsibility to manage our division's clinical and research efforts as well as coordinate care delivery for the at-risk population in Baltimore and surrounding areas. Many patients at the highest risk for CKD do not have access to screening, and there is no convenient method for at home/easily accessible devices for patients who require routine monitoring of urine albumin for follow up of their glomerular disease. Your proposed device and health delivery platform has an opportunity to transform this space by making screening feasible at every health encounter and potentially at home. "
When asked about this support letter from Dr. Parikh, Dr. Tangri, a member of the Company's scientific development team and one of the co-founders of the device, stated that "according to the CDC more than 100 million Americans are at risk for having CKD, and more than 30 million already have the disease and are at risk for kidney failure and heart attacks. I am delighted that Dr. Parikh shares our vision for improving screening and treatment for patients with or at risk of CKD, and is a believer in upstream interventions that can identify high risk patients for early treatment and disease prevention."
Company Article Featured in Stat News
The Company is also excited to announce its feature in Stat News, a trusted journalistic website with a focus on health, medicine, and the life sciences.
About the Company
Health Logic Interactive, through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient's smartphones and digital continued care platforms. The Company plans to use its patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient's smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.healthlogicinteractive.com
Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Notes
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's belief that it will receive approval from the United States Food and Drug Administration for its device, that the device has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD, the potential of the device to make screening feasible at every health encounter and potentially at home, and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's Management's Discussion and Analysis for the year ended December 31, 2020. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/health-logic-interactive-receives-letter-of-support-from-the-chief-of-the-division-of-nephrology-at-johns-hopkins-university-school-of-medicine-301299473.html
SOURCE Health Logic Interactive Inc.
FAQ
What support did Health Logic Interactive receive from Johns Hopkins?
What is the significance of the letter from Dr. Parikh for Health Logic Interactive?
How does Health Logic's technology aim to help CKD patients?
When was the press release issued by Health Logic Interactive?
Where can I find more information about Health Logic Interactive Inc.?
